Update on Imaging of Ovarian Cancer

被引：24

作者：

Forstner R. ^{[1
]}

Meissnitzer M. ^{[1
]}

Cunha T.M. ^{[2
]}

机构：

[1] Department of Radiology, Landeskliniken Salzburg, Paracelsus Medical University, Müllner Hauptstr. 48, Salzburg

[2] Serviço de Radiologia, Instituto Português de Oncologia de Lisboa Francisco Gentil, Rua Prof. Lima Basto, Lisbon

来源：

Current Radiology Reports | / 4卷 / 6期

关键词：

Computed tomography; Diagnostic imaging; Neoplasm staging; Ovarian neoplasm/diagnosis; Ovarian neoplasm/therapy;

D O I：

10.1007/s40134-016-0157-9

中图分类号：

学科分类号：

摘要：

This review will make familiar with new concepts in ovarian cancer and their impact on radiological practice. Disseminated peritoneal spread and ascites are typical of the most common (70–80 %) cancer type, high-grade serous ovarian cancer. Other cancer subtypes differ in origin, precursors, and imaging features. Expert sonography allows excellent risk assessment in adnexal masses. Owing to its high specificity, complementary MRI improves characterization of indeterminate lesions. Major changes in the new FIGO staging classification include fusion of fallopian tube and primary ovarian cancer and the subcategory stage IIIA1 for retroperitoneal lymph node metastases only. Inguinal lymph nodes, cardiophrenic lymph nodes, and umbilical metastases are classified as distant metastases (stage IVB). In multidisciplinary conferences (MDC), CT has been used to predict the success of cytoreductive surgery. Resectability criteria have to be specified and agreed on in MDC. Limitations in detection of metastases may be overcome using advanced MRI techniques. © 2016, The Author(s).

引用

共 57 条

[1]

Schmid B.C., Oehler M.K., New perspectives in ovarian cancer treatment, Maturitas, 77, pp. 128-136, (2014)

[2]

Hohn A.K., Einenekel J., Wittekind C., Horn L.C., Neue FIGO-Klassifikation des Ovarial-Tuben und primären Peritonealkarzinoms, Pathologe, 35, pp. 322-326, (2014)

[3]

Kurman R.J., Carcangiu M.L., Herrington C.S., Young R.H., Classification of tumours of the ovary, WHO classification of tumours, Vol. 6. 4th ed

[4]

Lawrenson K., Gyther S.A., Ovarian cancer: a clinical challenge that needs some basic answers, PLOS Med., 6, 2e, (2009)

[5]

Kurman R.J., Shih I.M., Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer–shifting the paradigm, Hum Pathol, 42, pp. 918-931, (2011)

[6]

Kurman R.J., Shih I.M., The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory, Am J Surg Pathol, 34, pp. 433-443, (2010)

[7]

Banerjee S., Kaye S.B., New strategies in the treatment of ovarian cancer: current clinical perspectives and future potential, Clin Cancer Res, 19, pp. 961-968, (2013)

[8]

Sala E., Kataoka M.Y., Priest A.N., Gill A.B., Et al., Advanced ovarian cancer: multiparametric MR imaging demonstrates response-and metastasis-specific effects, Radiology, 263, pp. 49-159, (2012)

[9]

Lalwani N., Prassad S.R., Vikram R., Shanboghue A.K., Et al., Histologic, molecular, and cytogenetic features of ovarian cancers: implication for diagnosis and treatment, RadioGraphics, 31, pp. 625-646, (2011)

[10]

Vargas H.A., Micco M., Hong S.I., Goldmann D.A., Et al., Association between morphologic CT imaging traits and prognostically relevant signatures in women with high-grade serous ovarian cancer. A hypothesis-generating study, Radiology, 274, pp. 742-751, (2015)

← 1 2 3 4 5 6 →